Myeloid-derived suppressor cells (MDSCs) in brain cancer: challenges and therapeutic strategies

被引：0
作者：
Mohammad Salemizadeh Parizi
Fatemeh Salemizadeh Parizi
Saeed Abdolhosseini
Shohreh Vanaei
Ali Manzouri
Farnoosh Ebrahimzadeh
机构：
[1] University of Houston,Department of Biomedical Engineering
[2] Binghamton University,Department of Biomedical Engineering
[3] University of Tehran,Department of Electrical Engineering
[4] Northeastern University,Department of Biomedical Engineering
[5] Sabzevar University of Medical Sciences,School of Medicine
[6] Mashhad University of Medical Sciences,Department of Internal Medicine, Faculty of Medicine
来源：
Inflammopharmacology | 2021年 / 29卷
关键词：
Brain cancer; Cancer therapy; Immunotherapy; MDSC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The most fatal malignancy of the central nervous system (CNS) is glioblastoma. Brain cancer is a ‘cold’ tumor because of fewer immunoregulatory cells and more immunosuppressive cells. Due to the cold nature of brain cancers, conventional treatments which are used to manage glioma patients show little effectiveness. Glioma patients even showed resistance to immune checkpoint blockade (ICB) and no significant efficacy. It has been shown that myeloid-derived suppressor cells (MDSCs) account for approximately 30–50% of the tumor mass in glioma. This study aimed to review MDSC function in brain cancer, as well as possible treatments and related challenges. In brain cancer and glioma, several differences in the context of MDSCs have been reported, including disagreements about the MDSC subtype that has the most inhibitory function in the brain, or inhibitory function of regulatory B cells (Bregs). There are also serious challenges in treating glioma patients. In addition to the cold nature of glioma, there are reports of an increase in MDSCs following conventional chemotherapy treatments. As a result, targeting MDSCs in combination with other therapies, such as ICB, is essential, and recent studies with the combination therapy approach have shown promising therapeutic effects in brain cancer.
引用
收藏
页码：1613 / 1624
页数：11
相关论文
共 610 条
  • [1] Alban TJ(2018)Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis JCI Insight 3 1191-689
  • [2] Alvarado AG(2020)Glioblastoma myeloid-derived suppressor cell subsets express differential macrophage migration inhibitory factor receptor profiles that can be targeted to reduce immune suppression Front Immunol 11 678-109
  • [3] Sorensen MD(2001)Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer J Immunol 166 99-14
  • [4] Bayik D(2020)Carboplatin chemoresistance is associated with CD11b+/Ly6C+ myeloid release and upregulation of TIGIT and LAG3/CD160 exhausted T cells Mol Immunol 118 1-1225
  • [5] Volovetz J(2020)Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas Nat Commun 11 1210-1230
  • [6] Serbinowski E(2020)Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner Cancer Discov 10 1219-564
  • [7] Onzi GR(2017)Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways J Neurosurg 127 557-IN923
  • [8] Alban TJ(2015)Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy foundation early phase clinical trials consortium phase II study Neuro Oncol 18 947-5682
  • [9] Bayik D(2011)B cells are critical to T-cell—mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma Neoplasia 13 5671-152
  • [10] Otvos B(2016)CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells Can Res 76 141-813
12345678910